1 Introduction to Research & Analysis Reports
1.1 Oral Drugs for Benign Prostatic Hyperplasia Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Oral Drugs for Benign Prostatic Hyperplasia Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Oral Drugs for Benign Prostatic Hyperplasia Overall Market Size
2.1 Global Oral Drugs for Benign Prostatic Hyperplasia Market Size: 2022 VS 2029
2.2 Global Oral Drugs for Benign Prostatic Hyperplasia Revenue, Prospects & Forecasts: 2018-2029
2.3 Global Oral Drugs for Benign Prostatic Hyperplasia Sales: 2018-2029
3 Company Landscape
3.1 Top Oral Drugs for Benign Prostatic Hyperplasia Players in Global Market
3.2 Top Global Oral Drugs for Benign Prostatic Hyperplasia Companies Ranked by Revenue
3.3 Global Oral Drugs for Benign Prostatic Hyperplasia Revenue by Companies
3.4 Global Oral Drugs for Benign Prostatic Hyperplasia Sales by Companies
3.5 Global Oral Drugs for Benign Prostatic Hyperplasia Price by Manufacturer (2018-2023)
3.6 Top 3 and Top 5 Oral Drugs for Benign Prostatic Hyperplasia Companies in Global Market, by Revenue in 2022
3.7 Global Manufacturers Oral Drugs for Benign Prostatic Hyperplasia Product Type
3.8 Tier 1, Tier 2 and Tier 3 Oral Drugs for Benign Prostatic Hyperplasia Players in Global Market
3.8.1 List of Global Tier 1 Oral Drugs for Benign Prostatic Hyperplasia Companies
3.8.2 List of Global Tier 2 and Tier 3 Oral Drugs for Benign Prostatic Hyperplasia Companies
4 Sights by Product
4.1 Overview
4.1.1 By Type – Global Oral Drugs for Benign Prostatic Hyperplasia Market Size Markets, 2022 & 2029
4.1.2 Alpha Blockers
4.1.3 5-alpha Reductase Inhibitors
4.1.4 Others
4.2 By Type – Global Oral Drugs for Benign Prostatic Hyperplasia Revenue & Forecasts
4.2.1 By Type – Global Oral Drugs for Benign Prostatic Hyperplasia Revenue, 2018-2023
4.2.2 By Type – Global Oral Drugs for Benign Prostatic Hyperplasia Revenue, 2024-2029
4.2.3 By Type – Global Oral Drugs for Benign Prostatic Hyperplasia Revenue Market Share, 2018-2029
4.3 By Type – Global Oral Drugs for Benign Prostatic Hyperplasia Sales & Forecasts
4.3.1 By Type – Global Oral Drugs for Benign Prostatic Hyperplasia Sales, 2018-2023
4.3.2 By Type – Global Oral Drugs for Benign Prostatic Hyperplasia Sales, 2024-2029
4.3.3 By Type – Global Oral Drugs for Benign Prostatic Hyperplasia Sales Market Share, 2018-2029
4.4 By Type – Global Oral Drugs for Benign Prostatic Hyperplasia Price (Manufacturers Selling Prices), 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application – Global Oral Drugs for Benign Prostatic Hyperplasia Market Size, 2022 & 2029
5.1.2 Hospitals
5.1.3 Drugstores
5.1.4 Others
5.2 By Application – Global Oral Drugs for Benign Prostatic Hyperplasia Revenue & Forecasts
5.2.1 By Application – Global Oral Drugs for Benign Prostatic Hyperplasia Revenue, 2018-2023
5.2.2 By Application – Global Oral Drugs for Benign Prostatic Hyperplasia Revenue, 2024-2029
5.2.3 By Application – Global Oral Drugs for Benign Prostatic Hyperplasia Revenue Market Share, 2018-2029
5.3 By Application – Global Oral Drugs for Benign Prostatic Hyperplasia Sales & Forecasts
5.3.1 By Application – Global Oral Drugs for Benign Prostatic Hyperplasia Sales, 2018-2023
5.3.2 By Application – Global Oral Drugs for Benign Prostatic Hyperplasia Sales, 2024-2029
5.3.3 By Application – Global Oral Drugs for Benign Prostatic Hyperplasia Sales Market Share, 2018-2029
5.4 By Application – Global Oral Drugs for Benign Prostatic Hyperplasia Price (Manufacturers Selling Prices), 2018-2029
6 Sights by Region
6.1 By Region – Global Oral Drugs for Benign Prostatic Hyperplasia Market Size, 2022 & 2029
6.2 By Region – Global Oral Drugs for Benign Prostatic Hyperplasia Revenue & Forecasts
6.2.1 By Region – Global Oral Drugs for Benign Prostatic Hyperplasia Revenue, 2018-2023
6.2.2 By Region – Global Oral Drugs for Benign Prostatic Hyperplasia Revenue, 2024-2029
6.2.3 By Region – Global Oral Drugs for Benign Prostatic Hyperplasia Revenue Market Share, 2018-2029
6.3 By Region – Global Oral Drugs for Benign Prostatic Hyperplasia Sales & Forecasts
6.3.1 By Region – Global Oral Drugs for Benign Prostatic Hyperplasia Sales, 2018-2023
6.3.2 By Region – Global Oral Drugs for Benign Prostatic Hyperplasia Sales, 2024-2029
6.3.3 By Region – Global Oral Drugs for Benign Prostatic Hyperplasia Sales Market Share, 2018-2029
6.4 North America
6.4.1 By Country – North America Oral Drugs for Benign Prostatic Hyperplasia Revenue, 2018-2029
6.4.2 By Country – North America Oral Drugs for Benign Prostatic Hyperplasia Sales, 2018-2029
6.4.3 US Oral Drugs for Benign Prostatic Hyperplasia Market Size, 2018-2029
6.4.4 Canada Oral Drugs for Benign Prostatic Hyperplasia Market Size, 2018-2029
6.4.5 Mexico Oral Drugs for Benign Prostatic Hyperplasia Market Size, 2018-2029
6.5 Europe
6.5.1 By Country – Europe Oral Drugs for Benign Prostatic Hyperplasia Revenue, 2018-2029
6.5.2 By Country – Europe Oral Drugs for Benign Prostatic Hyperplasia Sales, 2018-2029
6.5.3 Germany Oral Drugs for Benign Prostatic Hyperplasia Market Size, 2018-2029
6.5.4 France Oral Drugs for Benign Prostatic Hyperplasia Market Size, 2018-2029
6.5.5 U.K. Oral Drugs for Benign Prostatic Hyperplasia Market Size, 2018-2029
6.5.6 Italy Oral Drugs for Benign Prostatic Hyperplasia Market Size, 2018-2029
6.5.7 Russia Oral Drugs for Benign Prostatic Hyperplasia Market Size, 2018-2029
6.5.8 Nordic Countries Oral Drugs for Benign Prostatic Hyperplasia Market Size, 2018-2029
6.5.9 Benelux Oral Drugs for Benign Prostatic Hyperplasia Market Size, 2018-2029
6.6 Asia
6.6.1 By Region – Asia Oral Drugs for Benign Prostatic Hyperplasia Revenue, 2018-2029
6.6.2 By Region – Asia Oral Drugs for Benign Prostatic Hyperplasia Sales, 2018-2029
6.6.3 China Oral Drugs for Benign Prostatic Hyperplasia Market Size, 2018-2029
6.6.4 Japan Oral Drugs for Benign Prostatic Hyperplasia Market Size, 2018-2029
6.6.5 South Korea Oral Drugs for Benign Prostatic Hyperplasia Market Size, 2018-2029
6.6.6 Southeast Asia Oral Drugs for Benign Prostatic Hyperplasia Market Size, 2018-2029
6.6.7 India Oral Drugs for Benign Prostatic Hyperplasia Market Size, 2018-2029
6.7 South America
6.7.1 By Country – South America Oral Drugs for Benign Prostatic Hyperplasia Revenue, 2018-2029
6.7.2 By Country – South America Oral Drugs for Benign Prostatic Hyperplasia Sales, 2018-2029
6.7.3 Brazil Oral Drugs for Benign Prostatic Hyperplasia Market Size, 2018-2029
6.7.4 Argentina Oral Drugs for Benign Prostatic Hyperplasia Market Size, 2018-2029
6.8 Middle East & Africa
6.8.1 By Country – Middle East & Africa Oral Drugs for Benign Prostatic Hyperplasia Revenue, 2018-2029
6.8.2 By Country – Middle East & Africa Oral Drugs for Benign Prostatic Hyperplasia Sales, 2018-2029
6.8.3 Turkey Oral Drugs for Benign Prostatic Hyperplasia Market Size, 2018-2029
6.8.4 Israel Oral Drugs for Benign Prostatic Hyperplasia Market Size, 2018-2029
6.8.5 Saudi Arabia Oral Drugs for Benign Prostatic Hyperplasia Market Size, 2018-2029
6.8.6 UAE Oral Drugs for Benign Prostatic Hyperplasia Market Size, 2018-2029
7 Manufacturers & Brands Profiles
7.1 Eli Lilly
7.1.1 Eli Lilly Company Summary
7.1.2 Eli Lilly Business Overview
7.1.3 Eli Lilly Oral Drugs for Benign Prostatic Hyperplasia Major Product Offerings
7.1.4 Eli Lilly Oral Drugs for Benign Prostatic Hyperplasia Sales and Revenue in Global (2018-2023)
7.1.5 Eli Lilly Key News & Latest Developments
7.2 GlaxoSmithKline
7.2.1 GlaxoSmithKline Company Summary
7.2.2 GlaxoSmithKline Business Overview
7.2.3 GlaxoSmithKline Oral Drugs for Benign Prostatic Hyperplasia Major Product Offerings
7.2.4 GlaxoSmithKline Oral Drugs for Benign Prostatic Hyperplasia Sales and Revenue in Global (2018-2023)
7.2.5 GlaxoSmithKline Key News & Latest Developments
7.3 Astellas Pharma
7.3.1 Astellas Pharma Company Summary
7.3.2 Astellas Pharma Business Overview
7.3.3 Astellas Pharma Oral Drugs for Benign Prostatic Hyperplasia Major Product Offerings
7.3.4 Astellas Pharma Oral Drugs for Benign Prostatic Hyperplasia Sales and Revenue in Global (2018-2023)
7.3.5 Astellas Pharma Key News & Latest Developments
7.4 Sanofi
7.4.1 Sanofi Company Summary
7.4.2 Sanofi Business Overview
7.4.3 Sanofi Oral Drugs for Benign Prostatic Hyperplasia Major Product Offerings
7.4.4 Sanofi Oral Drugs for Benign Prostatic Hyperplasia Sales and Revenue in Global (2018-2023)
7.4.5 Sanofi Key News & Latest Developments
7.5 Pfizer
7.5.1 Pfizer Company Summary
7.5.2 Pfizer Business Overview
7.5.3 Pfizer Oral Drugs for Benign Prostatic Hyperplasia Major Product Offerings
7.5.4 Pfizer Oral Drugs for Benign Prostatic Hyperplasia Sales and Revenue in Global (2018-2023)
7.5.5 Pfizer Key News & Latest Developments
7.6 Abbott
7.6.1 Abbott Company Summary
7.6.2 Abbott Business Overview
7.6.3 Abbott Oral Drugs for Benign Prostatic Hyperplasia Major Product Offerings
7.6.4 Abbott Oral Drugs for Benign Prostatic Hyperplasia Sales and Revenue in Global (2018-2023)
7.6.5 Abbott Key News & Latest Developments
7.7 Allergan
7.7.1 Allergan Company Summary
7.7.2 Allergan Business Overview
7.7.3 Allergan Oral Drugs for Benign Prostatic Hyperplasia Major Product Offerings
7.7.4 Allergan Oral Drugs for Benign Prostatic Hyperplasia Sales and Revenue in Global (2018-2023)
7.7.5 Allergan Key News & Latest Developments
7.8 TEVA
7.8.1 TEVA Company Summary
7.8.2 TEVA Business Overview
7.8.3 TEVA Oral Drugs for Benign Prostatic Hyperplasia Major Product Offerings
7.8.4 TEVA Oral Drugs for Benign Prostatic Hyperplasia Sales and Revenue in Global (2018-2023)
7.8.5 TEVA Key News & Latest Developments
7.9 Viatris
7.9.1 Viatris Company Summary
7.9.2 Viatris Business Overview
7.9.3 Viatris Oral Drugs for Benign Prostatic Hyperplasia Major Product Offerings
7.9.4 Viatris Oral Drugs for Benign Prostatic Hyperplasia Sales and Revenue in Global (2018-2023)
7.9.5 Viatris Key News & Latest Developments
7.10 Novartis
7.10.1 Novartis Company Summary
7.10.2 Novartis Business Overview
7.10.3 Novartis Oral Drugs for Benign Prostatic Hyperplasia Major Product Offerings
7.10.4 Novartis Oral Drugs for Benign Prostatic Hyperplasia Sales and Revenue in Global (2018-2023)
7.10.5 Novartis Key News & Latest Developments
7.11 Merck
7.11.1 Merck Company Summary
7.11.2 Merck Oral Drugs for Benign Prostatic Hyperplasia Business Overview
7.11.3 Merck Oral Drugs for Benign Prostatic Hyperplasia Major Product Offerings
7.11.4 Merck Oral Drugs for Benign Prostatic Hyperplasia Sales and Revenue in Global (2018-2023)
7.11.5 Merck Key News & Latest Developments
8 Global Oral Drugs for Benign Prostatic Hyperplasia Production Capacity, Analysis
8.1 Global Oral Drugs for Benign Prostatic Hyperplasia Production Capacity, 2018-2029
8.2 Oral Drugs for Benign Prostatic Hyperplasia Production Capacity of Key Manufacturers in Global Market
8.3 Global Oral Drugs for Benign Prostatic Hyperplasia Production by Region
9 Key Market Trends, Opportunity, Drivers and Restraints
9.1 Market Opportunities & Trends
9.2 Market Drivers
9.3 Market Restraints
10 Oral Drugs for Benign Prostatic Hyperplasia Supply Chain Analysis
10.1 Oral Drugs for Benign Prostatic Hyperplasia Industry Value Chain
10.2 Oral Drugs for Benign Prostatic Hyperplasia Upstream Market
10.3 Oral Drugs for Benign Prostatic Hyperplasia Downstream and Clients
10.4 Marketing Channels Analysis
10.4.1 Marketing Channels
10.4.2 Oral Drugs for Benign Prostatic Hyperplasia Distributors and Sales Agents in Global
11 Conclusion
12 Appendix
12.1 Note
12.2 Examples of Clients
12.3 Disclaimer
世界の前立腺肥大症用経口治療薬市場予測2023-2029：アルファ遮断薬、5アルファ還元酵素阻害薬、その他 |
| 【英語タイトル】Oral Drugs for Benign Prostatic Hyperplasia Market, Global Outlook and Forecast 2023-2029 | |
 | ・商品コード：MMG23JU5841 ・発行会社（調査会社）：Market Monitor Global ・発行日：2023年6月 ・ページ数：78 ・レポート言語：英語 ・レポート形式：PDF ・納品方法：Eメール（受注後2-3営業日） ・調査対象地域：グローバル、北米、アメリカ、ヨーロッパ、アジア、日本、中国、東南アジア、インド、南米、中東・アフリカなど ・産業分野：医薬品＆医療 |
| Single User（1名様閲覧用） | USD3,250 ⇒換算￥494,000 | 見積依頼/購入/質問フォーム |
| Multi User（20名様閲覧用） | USD4,225 ⇒換算￥642,200 | 見積依頼/購入/質問フォーム |
| Enterprise User（閲覧人数制限なし） | USD4,875 ⇒換算￥741,000 | 見積依頼/購入/質問フォーム |
|
※販売価格オプションの説明 ※お支払金額：換算金額（日本円）＋消費税 ※納期：即日〜2営業日（3日以上かかる場合は別途表記又はご連絡） ※お支払方法：納品日＋5日以内に請求書を発行・送付（請求書発行日より2ヶ月以内に銀行振込、振込先：三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能） |
| 当調査レポートは次の情報を含め、世界の前立腺肥大症用経口治療薬市場規模と予測を収録しています。・世界の前立腺肥大症用経口治療薬市場：売上、2018年-2023年、2024年-2029年 ・世界の前立腺肥大症用経口治療薬市場：販売量、2018年-2023年、2024年-2029年 ・世界のトップ5企業、2022年 世界の前立腺肥大症用経口治療薬市場は2022年に000Mドルと評価され、予測期間中に000％のCAGRで2029年までに000Mドルに達すると予測されています。米国市場は2022年に000Mドルと推定されており、中国は2029年までに000Mドルに達すると予測されています。「アルファ遮断薬」セグメントは今後6年間、000%のCAGRで2029年までに000Mドルに成長すると予測されています。 前立腺肥大症用経口治療薬のグローバル主要企業は、Eli Lilly、 GlaxoSmithKline、 Astellas Pharma、 Sanofi、 Pfizer、 Abbott、 Allergan、 TEVA、 Viatris、 Novartis、 Merckなどです。2022年にトップ5企業がグローバル売上シェアの約000%を占めています。 MARKET MONITOR GLOBAL（MMG）は、前立腺肥大症用経口治療薬のメーカー、サプライヤー、流通業者、および業界の専門家を調査しました。これには、販売量、売上、需要、価格変動、製品タイプ、最近の動向と計画、産業トレンド、成長要因、課題、阻害要因、潜在的なリスクなどが含まれます。 【セグメント別市場分析】 世界の前立腺肥大症用経口治療薬市場：タイプ別、2018年-2023年、2024年-2029年 世界の前立腺肥大症用経口治療薬市場：タイプ別市場シェア、2022年 ・アルファ遮断薬、5アルファ還元酵素阻害薬、その他 世界の前立腺肥大症用経口治療薬市場：用途別、2018年-2023年、2024年-2029年 世界の前立腺肥大症用経口治療薬市場：用途別市場シェア、2022年 ・病院、ドラッグストア、その他 世界の前立腺肥大症用経口治療薬市場：地域・国別、2018年-2023年、2024年-2029年 世界の前立腺肥大症用経口治療薬市場：地域別市場シェア、2022年 ・北米：アメリカ、カナダ、メキシコ ・ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア ・アジア：中国、日本、韓国、東南アジア、インド ・南米：ブラジル、アルゼンチン ・中東・アフリカ：トルコ、イスラエル、サウジアラビア、UAE 【競合分析】 また、当レポートは主要な市場参加者の分析を提供します。 ・主要企業における前立腺肥大症用経口治療薬のグローバル売上、2018年-2023年 ・主要企業における前立腺肥大症用経口治療薬のグローバル売上シェア、2022年 ・主要企業における前立腺肥大症用経口治療薬のグローバル販売量、2018年-2023年 ・主要企業における前立腺肥大症用経口治療薬のグローバル販売量シェア、2022年 さらに、当レポートは主要企業のプロファイルを提示します。 Eli Lilly、 GlaxoSmithKline、 Astellas Pharma、 Sanofi、 Pfizer、 Abbott、 Allergan、 TEVA、 Viatris、 Novartis、 Merck ************************************************************* ・調査・分析レポートの概要 前立腺肥大症用経口治療薬市場の定義 市場セグメント 世界の前立腺肥大症用経口治療薬市場概要 当レポートの特徴・ベネフィット 調査手法と情報源 ・世界の前立腺肥大症用経口治療薬市場規模 世界の前立腺肥大症用経口治療薬市場規模：2022年 VS 2029年 世界の前立腺肥大症用経口治療薬市場規模と予測 2018年-2029年 ・競争状況 グローバルトップ企業 売上ベースでのグローバルトップ企業 企業別グローバルでの前立腺肥大症用経口治療薬の売上 グローバルトップ3およびトップ5企業、2022年売上ベース グローバル企業の前立腺肥大症用経口治療薬製品タイプ グローバルにおけるティア1、ティア2、ティア3企業 ・タイプ別市場分析 タイプ区分：アルファ遮断薬、5アルファ還元酵素阻害薬、その他 前立腺肥大症用経口治療薬のタイプ別グローバル売上・予測 ・用途別市場分析 用途区分：病院、ドラッグストア、その他 前立腺肥大症用経口治療薬の用途別グローバル売上・予測 ・地域別市場分析 地域別前立腺肥大症用経口治療薬市場規模 2022年と2029年 地域別前立腺肥大症用経口治療薬売上・予測 北米市場：アメリカ、カナダ、メキシコ ヨーロッパ市場：ドイツ、フランス、イギリス、イタリア、ロシア アジア市場：中国、日本、韓国、東南アジア、インド 南米市場：ブラジル、アルゼンチン 中東・アフリカ市場：トルコ、イスラエル、サウジアラビア、UAE ・主要企業のプロファイル（企業概要、事業概要、主要製品、売上、ニュースなど） Eli Lilly、 GlaxoSmithKline、 Astellas Pharma、 Sanofi、 Pfizer、 Abbott、 Allergan、 TEVA、 Viatris、 Novartis、 Merck ... |
BPH is an enlarged prostate. The prostate goes through two main growth cycles during a man’s life. The first occurs early in puberty, when the prostate doubles in size. The second phase of growth starts around age 25 and goes on for most of the rest of a man’s life. BPH most often occurs during this second growth phase.
This report aims to provide a comprehensive presentation of the global market for Oral Drugs for Benign Prostatic Hyperplasia, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Oral Drugs for Benign Prostatic Hyperplasia. This report contains market size and forecasts of Oral Drugs for Benign Prostatic Hyperplasia in global, including the following market information:
Global Oral Drugs for Benign Prostatic Hyperplasia Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global Oral Drugs for Benign Prostatic Hyperplasia Market Sales, 2018-2023, 2024-2029, (K Units)
Global top five Oral Drugs for Benign Prostatic Hyperplasia companies in 2022 (%)
The global Oral Drugs for Benign Prostatic Hyperplasia market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is Forecast to Reach $ Million.
Alpha Blockers Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Oral Drugs for Benign Prostatic Hyperplasia include Eli Lilly, GlaxoSmithKline, Astellas Pharma, Sanofi, Pfizer, Abbott, Allergan, TEVA and Viatris, etc. in 2022, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Oral Drugs for Benign Prostatic Hyperplasia manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Oral Drugs for Benign Prostatic Hyperplasia Market, by Type, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Oral Drugs for Benign Prostatic Hyperplasia Market Segment Percentages, by Type, 2022 (%)
Alpha Blockers
5-alpha Reductase Inhibitors
Others
Global Oral Drugs for Benign Prostatic Hyperplasia Market, by Application, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Oral Drugs for Benign Prostatic Hyperplasia Market Segment Percentages, by Application, 2022 (%)
Hospitals
Drugstores
Others
Global Oral Drugs for Benign Prostatic Hyperplasia Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Oral Drugs for Benign Prostatic Hyperplasia Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Oral Drugs for Benign Prostatic Hyperplasia revenues in global market, 2018-2023 (Estimated), ($ millions)
Key companies Oral Drugs for Benign Prostatic Hyperplasia revenues share in global market, 2022 (%)
Key companies Oral Drugs for Benign Prostatic Hyperplasia sales in global market, 2018-2023 (Estimated), (K Units)
Key companies Oral Drugs for Benign Prostatic Hyperplasia sales share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Eli Lilly
GlaxoSmithKline
Astellas Pharma
Sanofi
Pfizer
Abbott
Allergan
TEVA
Viatris
Novartis
Merck
Outline of Major Chapters:
Chapter 1: Introduces the definition of Oral Drugs for Benign Prostatic Hyperplasia, market overview.
Chapter 2: Global Oral Drugs for Benign Prostatic Hyperplasia market size in revenue and volume.
Chapter 3: Detailed analysis of Oral Drugs for Benign Prostatic Hyperplasia manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Oral Drugs for Benign Prostatic Hyperplasia in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global Oral Drugs for Benign Prostatic Hyperplasia capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.
❖ レポートの目次 ❖
| ★調査レポート[世界の前立腺肥大症用経口治療薬市場予測2023-2029：アルファ遮断薬、5アルファ還元酵素阻害薬、その他] (コード：MMG23JU5841)販売に関する免責事項を必ずご確認ください。 |
| ★調査レポート[世界の前立腺肥大症用経口治療薬市場予測2023-2029：アルファ遮断薬、5アルファ還元酵素阻害薬、その他]についてメールでお問い合わせ |
